Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Gemma Salvadó(Lund University), Oskar Hansson(Eli Lilly (United States)), Randall J. Bateman(Washington University in St. Louis), Sebastian Palmqvist(Skåne University Hospital), Rik Ossenkoppele(Malmö University), Erik Stomrud(Lund University), John C. Morris(Washington University in St. Louis), Nicolas R. Barthélemy(Washington University in St. Louis), Suzanne E. Schindler(Washington University in St. Louis), Shorena Janelidze(Lund University), Jacob W. Vogel(Malmö University), Charles D. Chen(Massachusetts General Hospital), Kanta Horie(Washington University in St. Louis), Andrew J. Aschenbrenner(Washington University in St. Louis), David M. Holtzman(Hope Center for Neurological Disorders), Tammie L.S. Benzinger(Washington University in St. Louis), Brian A. Gordon(Mallinckrodt (United States)), Alexa Pichet Binette(Lund University)
Cited by 108
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
|Immunity|2017|3k
Alzheimer disease
|Nature Reviews Disease Primers|2021|2.4k